Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial

BACKGROUND: In the phase 3 GRID trial, regorafenib improved progression-free survival (PFS) independent of KIT mutations in exons 9 and 11. In this retrospective, exploratory analysis of the GRID trial, we investigated whether a more comprehensive KIT mutation analysis could identify mutations that...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeffers, Michael, Kappeler, Christian, Kuss, Iris, Beckmann, Georg, Mehnert, Daniel H., Fredebohm, Johannes, Teufel, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013336/
https://www.ncbi.nlm.nih.gov/pubmed/35050442
http://dx.doi.org/10.1007/s10120-021-01274-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013336/
https://www.ncbi.nlm.nih.gov/pubmed/35050442
http://dx.doi.org/10.1007/s10120-021-01274-6

Ejemplares similares